InMode Ltd. Ordinary Shares - INMD STOCK NEWS

La Belle Vie MedSpa & Wellness Center announces the grand opening of the Oasis Treatment Tent, a COVID-friendly outdoor setup featuring InMode's non-invasive Evolve and Forma treatments. Evolve is a hands-free platform designed for skin remodeling and muscle toning, reducing in-person interactions. Forma utilizes bipolar radiofrequency to enhance skin texture and is safe for all skin types. The tent opens on November 28, providing an innovative aesthetic solution while prioritizing health and safety.

InMode Ltd. (Nasdaq: INMD) reported record Q3 2020 revenues of $59.7 million, a 49% increase year-over-year. The company achieved a GAAP net income of $23.9 million, up from $16.2 million in Q3 2019, resulting in a diluted EPS of $0.57. Key revenue drivers included its proprietary surgical technology platforms and new hands-free solutions. Cash position stands at $234.3 million. Management anticipates 2020 revenues to be between $192 million and $195 million, with expected non-GAAP gross margins of 84%-86%.

Nanowear has received FDA Class II 510(k) clearance for SimpleSENSE, a groundbreaking cloth-based diagnostic platform. This multi-parameter remote diagnostic undergarment synchronously monitors cardiac, pulmonary, and circulatory health, capturing over 100 million data points daily. With the demand for telemedicine rising, SimpleSENSE offers clinicians a powerful tool for early patient intervention. As a response to the COVID-19 pandemic, Nanowear aims to assist in remote diagnostics across various healthcare areas. The company also plans to continue clinical trials related to heart failure and COVID-19.

InMode Ltd. (Nasdaq: INMD) announced the US Patent and Trademark Office has granted Patent No. 10.799.285 for its Morpheus8 full body fractional radiofrequency technology. This patent is part of InMode's strategy to protect its intellectual property and enhance shareholder value. The company has actively issued cease and desist notices to North American companies infringing on this patent. InMode's ongoing R&D efforts have established it as a leader in the medical aesthetics field, particularly with its Morpheus8 Subdermal Adipose Remodeling device.

InMode Ltd. (Nasdaq: INMD) announced a peer-reviewed study published in Lasers in Surgery and Medicine exploring the risks associated with plume emissions during skin resurfacing procedures. Conducted by leading medical professionals, the study found that the Erbium: YAG laser emitted over four times more particles than InMode's Morpheus8 fractional RF device, which showed minimal plume emission. The findings support the safety of Morpheus8 technology in elective procedures, according to InMode executives.

InMode Ltd. (Nasdaq: INMD), a leader in medical technologies, announced participation in two virtual investor conferences. The Jefferies Virtual Global Healthcare Conference will feature a presentation by CEO Moshe Mizrahy on November 18, 2020, at 10:50 a.m. EST. Following this, at 11:30 a.m. EST on November 19, 2020, CFO Yair Malca will engage in a fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum. Live webcasts will be available at InMode's investor page, archived for 90 days.

InMode Ltd. (Nasdaq: INMD) has launched the Morpheus8 Body Multi-pulse Burst Radiofrequency Technology, enhancing the previously released Morpheus8 Body Subdermal Adipose Remodeling Device. This innovative technology employs a three-level sequential RF energy deployment, which reduces treatment times and minimizes skin injury. InMode's President highlighted that this launch solidifies the company’s leadership in fractional treatments. The Morpheus8 Burst technology is based on the Vulcanization Process, aiming to improve skin elasticity and strength.

InMode Ltd. (INMD) announced it will release third-quarter 2020 financial results on November 12, 2020. Preliminary results indicate record revenues between $59.2 million and $59.5 million and non-GAAP earnings per diluted share between $0.60 and $0.62. For the full year, revenue guidance is updated to a range of $192 million to $195 million.

This highlights InMode's robust performance driven by its innovative medical technologies, which the CEO claims are becoming the gold standard in minimally invasive surgical procedures.

InMode Ltd. (Nasdaq: INMD) has announced a share repurchase program for up to 1 million ordinary shares, approved by its Board of Directors. This initiative aims to enhance shareholder value amid anticipated increased demand for its medical technologies, particularly as elective surgeries resume. With a robust financial position and ongoing product launches, management expresses confidence in capturing market share and expanding its operations. The buyback will be funded by existing cash resources, allowing flexibility in execution.